Browse drugs

…Introduction Upadacitinib (UPA) is an oral, selective, reversible janus kinase (JAK) 1 in…

…Introduction Upadacitinib (UPA), an oral, reversible Janus kinase inhibitor is approved f…

…. cData missing for 14 patients.BA, bempedoic acid; BA+EZE-FDC. Bempedoic acid/ezetimibe fixed-dose combination; HeFH, heterozygous familial h…

…rgoing percutaneous coronary intervention (PCI), ticagrelor and prasugrel are established potent P2Y12 inhibitors. Selection between thes…

… predicting progression of SSc-ILD while serum concentration of PRDX4 are associated with overall progression of SSc.…

…its, BMI, diabetes duration, HbA1c, ACR, triglycerides, LDL and statins treatment. Linear regression models on eGFR decline were perfor…

… lower mortality at 6 months, 1 year, and 3 years compared with alteplase, without increased intracerebral hemorrhage. Early cognitive im…

…5.06% (Medina), 94.78% (Nautilus), 87.37% (Trenza), and 89.08% (Neqstent), but estimates were based on smaller evidence bases and shorte…

…ad documented clinical response or remission after switching to ustekinumab. 2 patients not responding subsequently switched from ustekinum…

…rted at least one TEAE were 59.4%, 46.9%, and 53.2% for Obe-50, Obe-25, and PBO, respectively in ABTECT-1 and 61.0%, 50.9%, and 48.4% …

… history of receiving novel antidiabetic medications (SGLT2i or GLP-1RA). Sensitivity analyses were also conducted in participants with…

…quency (episodes per person or per unit time, as reported). (4) Insulin dosage: we extracted total daily dose (TDD) and weight-normaliz…